Loay Kassem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Loay Kassem has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Hamdy A. Azim
Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
4 shared publications- Emad Shash
Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
3 shared publications Isabelle Treilleux
Université de Lyon, Lyon, France
3 shared publications- Coralie Poulard
Université de Lyon, F-69000 Lyon, France
2 shared publications - Hamdy Abdel Azim
Department of Clinical Oncology Cairo University Cairo Egypt
2 shared publications - Julien Jacquemetton
INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in Archives of Public Health
- Vol. 84 (1) , 228
Advancing women’s health in Egypt: an economic evaluation of the presidential initiative for nationwide breast cancer early detection and treatment
Breast cancer (BC) is the leading cause of cancer-related mortality among women worldwide and poses a major public health and economic challenge in Egypt,
- 23 October 2026
- Published by Springer Nature in Archives of Public Health
- Vol. 84 (1) , 228
Open AccessAdvancing women’s health in Egypt: an economic evaluation of the presidential initiative for nationwide breast cancer early detection and treatment
Breast cancer (BC) is the leading cause of cancer-related mortality among women worldwide and poses a major public health and economic challenge in Egypt,
- 26 September 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (6) , 1741-1750
Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study
- 26 September 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (6) , 1741-1750
Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500108
Social Determinants Associated With the Advanced-Stage Diagnosis of Breast Cancer
PURPOSE: The majority of Egyptian patients with breast cancer (BC) present at advanced stages. We examined the sociodemographic and clinical factors associated with late presentation of BC. METHODS: A retrospective cohort study was conducted on patients who presented with BC between 2011 and 2020. Logistic regression analysis was used to examine the association between sociodemographic factors and advanced-stage BC. RESULTS: This cohort included 1,953 patients with a median age of 52 years. Among them, 1,098 (56.2%) patients were diagnosed at early stages, whereas 855 (43.8%) were diagnosed at advanced stages. Univariable logistic regression revealed several factors associated with advanced BC, including having a negative family history of BC (odds ratio [OR], 1.27 [95% CI, 1.05 to 1.54]), having no job (OR, 1.28 [95% CI, 1.06 to 1.53]), being married (OR, 1.27 [95% CI, 1.02 to 1.57]), rural residence (OR, 1.27 [95% CI, 1.02 to 1.57]), having more than three children (OR, 1.42 [95% CI, 1.15 to 1.75]), higher Ki67% score (OR, 1.01 [95% CI, 1.00 to 1.01]), having human epidermal growth factor receptor 2–overexpressed or triple-negative BC subtypes (OR, 1.44 [95% CI, 1.16 to 1.79]), and having tumor grade 2/3 (OR, 4.12 [95% CI, 1.58 to 10.77 and OR, 1.44 [95% CI, 1.16 to 1.79], respectively). In the multivariable logistic regression model, only higher Ki67% (adjusted odds ratio [aOR], 1.01 [95% CI, 1.00 to 1.02]), having no job (aOR, 1.44 [95% CI, 1.10 to 1.90]), and rural residence (aOR, 1.88 [95% CI, 1.03 to 3.42]) were significantly associated with advanced BC. CONCLUSION: This study concluded that having no job and rural residence are strongly associated with advanced BC. Raising public awareness is essential to encourage early detection of BC.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500108
Social Determinants Associated With the Advanced-Stage Diagnosis of Breast Cancer
PURPOSE: The majority of Egyptian patients with breast cancer (BC) present at advanced stages. We examined the sociodemographic and clinical factors associated with late presentation of BC. METHODS: A retrospective cohort study was conducted on patients who presented with BC between 2011 and 2020. Logistic regression analysis was used to examine the association between sociodemographic factors and advanced-stage BC. RESULTS: This cohort included 1,953 patients with a median age of 52 years. Among them, 1,098 (56.2%) patients were diagnosed at early stages, whereas 855 (43.8%) were diagnosed at advanced stages. Univariable logistic regression revealed several factors associated with advanced BC, including having a negative family history of BC (odds ratio [OR], 1.27 [95% CI, 1.05 to 1.54]), having no job (OR, 1.28 [95% CI, 1.06 to 1.53]), being married (OR, 1.27 [95% CI, 1.02 to 1.57]), rural residence (OR, 1.27 [95% CI, 1.02 to 1.57]), having more than three children (OR, 1.42 [95% CI, 1.15 to 1.75]), higher Ki67% score (OR, 1.01 [95% CI, 1.00 to 1.01]), having human epidermal growth factor receptor 2–overexpressed or triple-negative BC subtypes (OR, 1.44 [95% CI, 1.16 to 1.79]), and having tumor grade 2/3 (OR, 4.12 [95% CI, 1.58 to 10.77 and OR, 1.44 [95% CI, 1.16 to 1.79], respectively). In the multivariable logistic regression model, only higher Ki67% (adjusted odds ratio [aOR], 1.01 [95% CI, 1.00 to 1.02]), having no job (aOR, 1.44 [95% CI, 1.10 to 1.90]), and rural residence (aOR, 1.88 [95% CI, 1.03 to 3.42]) were significantly associated with advanced BC. CONCLUSION: This study concluded that having no job and rural residence are strongly associated with advanced BC. Raising public awareness is essential to encourage early detection of BC.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400841
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
PURPOSE: The prognostic significance of BRCA1/2 mutation and RB1 alteration (Alt) in patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor-2–negative (HER2–) breast cancer (BC) treated with endocrine therapy (ET) ± cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains unresolved. This meta-analysis aimed to define their influence on therapy outcomes in the early and metastatic stages. MATERIALS AND METHODS: We systematically searched PubMed, Cochrane, and Google Scholar databases. Primary end points included disease-free (or progression-free) survival (DFS/PFS) and overall survival (OS) according to BRCA1/2 mutation or RB1 Alt status. A separate analysis of individual-patient data for metastatic HR+/HER2– BC extracted from MSK-MET project was performed. RESULTS: Twenty-two studies comprising 34,960 patients were eligible for meta-analysis. In the early setting, in eight studies (n = 7,857 patients with HR+ BC received ET), BRCA1/2 mutant type ( MT ) was associated with a marginally significant worse DFS (hazard ratio, 1.64 [95% CI, 1 to 2.69]; P = .05) and a significantly worse OS (hazard ratio, 1.52 [95% CI, 1.20 to 1.92]; P = .0006) versus BRCA wild-type ( WT ). In the metastatic setting, in 11 studies (n = 12,670 patients received ET+ CDK4/6i), BRCA1/2 mutation was associated with a significantly worse PFS (hazard ratio, 1.87 [95% CI, 1.45 to 2.41]; P < .00001) and OS (hazard ratio, 1.38 [95% CI, 1.15 to 1.65]; P = .0005) versus BRCA WT . The individual-patient data confirmed the poorer prognosis of BRCA2 MT and RB1 Alt , but not BRCA1 MT , and a significant co-occurrence of RB1 loss of heterozygosity ( LOH ) among BRCA2 MT carriers. CONCLUSION: The current analysis adds to the body of evidence supporting the inferior outcomes of ET± CDK4/6i in BRCA MT compared with BRCA WT . Given its significant coexistence with RB1 LOH, BRCA2 MT BC seems uniquely resistant to ET± CDK4/6i, a point that is profoundly different from sporadic or even BRCA1 MT HR+/HER2– BC.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400841
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
PURPOSE: The prognostic significance of BRCA1/2 mutation and RB1 alteration (Alt) in patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor-2–negative (HER2–) breast cancer (BC) treated with endocrine therapy (ET) ± cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains unresolved. This meta-analysis aimed to define their influence on therapy outcomes in the early and metastatic stages. MATERIALS AND METHODS: We systematically searched PubMed, Cochrane, and Google Scholar databases. Primary end points included disease-free (or progression-free) survival (DFS/PFS) and overall survival (OS) according to BRCA1/2 mutation or RB1 Alt status. A separate analysis of individual-patient data for metastatic HR+/HER2– BC extracted from MSK-MET project was performed. RESULTS: Twenty-two studies comprising 34,960 patients were eligible for meta-analysis. In the early setting, in eight studies (n = 7,857 patients with HR+ BC received ET), BRCA1/2 mutant type ( MT ) was associated with a marginally significant worse DFS (hazard ratio, 1.64 [95% CI, 1 to 2.69]; P = .05) and a significantly worse OS (hazard ratio, 1.52 [95% CI, 1.20 to 1.92]; P = .0006) versus BRCA wild-type ( WT ). In the metastatic setting, in 11 studies (n = 12,670 patients received ET+ CDK4/6i), BRCA1/2 mutation was associated with a significantly worse PFS (hazard ratio, 1.87 [95% CI, 1.45 to 2.41]; P < .00001) and OS (hazard ratio, 1.38 [95% CI, 1.15 to 1.65]; P = .0005) versus BRCA WT . The individual-patient data confirmed the poorer prognosis of BRCA2 MT and RB1 Alt , but not BRCA1 MT , and a significant co-occurrence of RB1 loss of heterozygosity ( LOH ) among BRCA2 MT carriers. CONCLUSION: The current analysis adds to the body of evidence supporting the inferior outcomes of ET± CDK4/6i in BRCA MT compared with BRCA WT . Given its significant coexistence with RB1 LOH, BRCA2 MT BC seems uniquely resistant to ET± CDK4/6i, a point that is profoundly different from sporadic or even BRCA1 MT HR+/HER2– BC.
- Open Access
- 21 February 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (8) , e41632
Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis
Background: The management of early breast cancer (BC) includes breast-conserving surgery (BCS), postoperative radiation therapy (PORT) and systemic therapy. Therefore, we aim at evaluating all the efficacy endpoints for PORT compared to no PORT in older women with early-stage BC. Method: We searched PubMed, Web of Science, Cochrane, and Scopus databases from inception up to May 2024 for randomized controlled trials (RCTs) where patients were randomized into either PORT vs no PORT. The following outcomes were studied: any local recurrence, nodal recurrence, contralateral BC, distant relapse, all-causes and cancer-specific mortality. Result: Seven eligible RCTs with a total of 4860 patients were included; 2435 of them received PORT; and 2425 did not. All patients had a node-negative disease, with 84.4% older than 60 years and only 10.4% had tumors larger than 2 cm. Patients in both treatment arms were offered adjuvant endocrine therapy e.g. tamoxifen and anastrozole. The median follow-up was 9.7 years (95% CI: 5.1–11.3). The survival risk for any local recurrence for patients with no radiotherapy was significantly higher than for those who used PORT (HR: 6.3; 95% CI: 4.17–9.52). Also, patients in the PORT arm had a significantly lower risk of nodal recurrence (risk of recurrence (RR): 0.28, 95% CI: 0.11–0.72, P = .009). However, PORT was not associated with a significant reduction in the risk of contralateral BC, distant relapse, BC-specific mortality or all-cause mortality (RR: 0.883, 1.52, 1.12, 0.995, respectively). Conclusion: Postoperative radiotherapy significantly reduces local and regional recurrence following BCS in early estrogen receptor-positive elderly BC with limited value on distant recurrence or mortality. The risk-benefit ratio should be determined for every patient to avoid overtreatment of a significant proportion of patients.
- 21 February 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (8) , e41632
Open AccessAdjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis
Background: The management of early breast cancer (BC) includes breast-conserving surgery (BCS), postoperative radiation therapy (PORT) and systemic therapy. Therefore, we aim at evaluating all the efficacy endpoints for PORT compared to no PORT in older women with early-stage BC. Method: We searched PubMed, Web of Science, Cochrane, and Scopus databases from inception up to May 2024 for randomized controlled trials (RCTs) where patients were randomized into either PORT vs no PORT. The following outcomes were studied: any local recurrence, nodal recurrence, contralateral BC, distant relapse, all-causes and cancer-specific mortality. Result: Seven eligible RCTs with a total of 4860 patients were included; 2435 of them received PORT; and 2425 did not. All patients had a node-negative disease, with 84.4% older than 60 years and only 10.4% had tumors larger than 2 cm. Patients in both treatment arms were offered adjuvant endocrine therapy e.g. tamoxifen and anastrozole. The median follow-up was 9.7 years (95% CI: 5.1–11.3). The survival risk for any local recurrence for patients with no radiotherapy was significantly higher than for those who used PORT (HR: 6.3; 95% CI: 4.17–9.52). Also, patients in the PORT arm had a significantly lower risk of nodal recurrence (risk of recurrence (RR): 0.28, 95% CI: 0.11–0.72, P = .009). However, PORT was not associated with a significant reduction in the risk of contralateral BC, distant relapse, BC-specific mortality or all-cause mortality (RR: 0.883, 1.52, 1.12, 0.995, respectively). Conclusion: Postoperative radiotherapy significantly reduces local and regional recurrence following BCS in early estrogen receptor-positive elderly BC with limited value on distant recurrence or mortality. The risk-benefit ratio should be determined for every patient to avoid overtreatment of a significant proportion of patients.
- Open Access
- 3 January 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 105-113
The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab
The cost-effectiveness of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab compared to neoadjuvant chemotherapy plus placebo followed by adjuvant placebo was assessed in high-risk, early-stage, triple-negative breast cancer patients from an Egyptian societal perspective over a lifetime horizon. A 4-state Markov cohort model was developed to compare the cost-effectiveness of pembrolizumab + chemotherapy/pembrolizumab vs chemotherapy alone for the treatment of high-risk, early-stage, triple-negative breast cancer. The model simulated the clinical course of high-risk, early-stage, triple-negative breast cancer across 4 health states: event-free survival, locoregional recurrence, distant metastasis, and death. Clinical inputs for the simulation were derived from modeling of efficacy and safety data collected in the KEYNOTE-522 trial. Direct medical costs and indirect costs were reported in 2022 Egyptian pounds [EGP] and converted to US dollars ($). Probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of model results. Compared with chemotherapy alone, pembrolizumab + chemotherapy/pembrolizumab led to expected gains of 2.92 life years and 2.25 quality-adjusted life years, respectively, while increasing overall treatment costs by EGP 491695 [$102436]. Incremental costs per year gained were EGP 218285 [$45476] per quality-adjusted life year and EGP 168223 [$35046] per life year, both of which were lower than the 2022 Egyptian cost-effectiveness threshold of EGP 398439 [$83008]. The findings of sensitivity analyses indicated that the model was robust across a range of inputs and assumptions. In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality of life and years of life gained.
- 3 January 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 105-113
Open AccessThe cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab
The cost-effectiveness of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab compared to neoadjuvant chemotherapy plus placebo followed by adjuvant placebo was assessed in high-risk, early-stage, triple-negative breast cancer patients from an Egyptian societal perspective over a lifetime horizon. A 4-state Markov cohort model was developed to compare the cost-effectiveness of pembrolizumab + chemotherapy/pembrolizumab vs chemotherapy alone for the treatment of high-risk, early-stage, triple-negative breast cancer. The model simulated the clinical course of high-risk, early-stage, triple-negative breast cancer across 4 health states: event-free survival, locoregional recurrence, distant metastasis, and death. Clinical inputs for the simulation were derived from modeling of efficacy and safety data collected in the KEYNOTE-522 trial. Direct medical costs and indirect costs were reported in 2022 Egyptian pounds [EGP] and converted to US dollars ($). Probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of model results. Compared with chemotherapy alone, pembrolizumab + chemotherapy/pembrolizumab led to expected gains of 2.92 life years and 2.25 quality-adjusted life years, respectively, while increasing overall treatment costs by EGP 491695 [$102436]. Incremental costs per year gained were EGP 218285 [$45476] per quality-adjusted life year and EGP 168223 [$35046] per life year, both of which were lower than the 2022 Egyptian cost-effectiveness threshold of EGP 398439 [$83008]. The findings of sensitivity analyses indicated that the model was robust across a range of inputs and assumptions. In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality of life and years of life gained.
- Open Access
- 20 September 2023
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (4) , 445-459
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
Background Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In many developing countries, including Egypt, the prevalence of BRCA1/2 mutations among women with breast cancer (BC) is unknown. Aim We aimed to determine the prevalence of deleterious germline BRCA mutations in Egyptian patients with breast cancer. Methods We report the results of a cohort study of 81 Egyptian patients with breast cancer who were tested for germline BRCA1/2 mutations during routine clinical practice, mostly for their young age of presentation, BC subtype, or presence of family history. In addition, we searched five databases to retrieve studies that reported the prevalence of BRCA1/2 mutation status in Egyptian women with BC. A systematic review of the literature was performed, including prospective and retrospective studies. Results In our patient cohort study, 12 patients (14.8%) were positive for either BRCA1/2 deleterious mutations. Moreover, 13 (16.1%) patients had a variant of unknown significance (VUS) of BRCA1/2 genes. Twelve studies were eligible for the systematic review, including 610 patients. A total of 19 deleterious germline mutations in BRCA1/2 were identified. The pooled prevalence of BRCA1/2 mutations was 40% (95% confidence interval 1–80%). Conclusion The reported prevalence was highly variable among the small-sized published studies that adopted adequate techniques. In our patient cohort, there was a high incidence of VUS in BRCA1/2 genes. Accordingly, there is an actual demand to conduct a prospective well-designed national study to accurately estimate the prevalence of BRCA1/2 mutations among patients with BC in Egypt.
- 20 September 2023
- Published by Springer Nature in Oncology and Therapy
- Vol. 11 (4) , 445-459
Open AccessThe Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
Background Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In many developing countries, including Egypt, the prevalence of BRCA1/2 mutations among women with breast cancer (BC) is unknown. Aim We aimed to determine the prevalence of deleterious germline BRCA mutations in Egyptian patients with breast cancer. Methods We report the results of a cohort study of 81 Egyptian patients with breast cancer who were tested for germline BRCA1/2 mutations during routine clinical practice, mostly for their young age of presentation, BC subtype, or presence of family history. In addition, we searched five databases to retrieve studies that reported the prevalence of BRCA1/2 mutation status in Egyptian women with BC. A systematic review of the literature was performed, including prospective and retrospective studies. Results In our patient cohort study, 12 patients (14.8%) were positive for either BRCA1/2 deleterious mutations. Moreover, 13 (16.1%) patients had a variant of unknown significance (VUS) of BRCA1/2 genes. Twelve studies were eligible for the systematic review, including 610 patients. A total of 19 deleterious germline mutations in BRCA1/2 were identified. The pooled prevalence of BRCA1/2 mutations was 40% (95% confidence interval 1–80%). Conclusion The reported prevalence was highly variable among the small-sized published studies that adopted adequate techniques. In our patient cohort, there was a high incidence of VUS in BRCA1/2 genes. Accordingly, there is an actual demand to conduct a prospective well-designed national study to accurately estimate the prevalence of BRCA1/2 mutations among patients with BC in Egypt.
- Open Access
- 17 July 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (8) , e17248
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of response to these anti‐estrogens to guide treatment decision. Here, using two independent cohorts of breast cancer patients, we identified nuclear PRMT5 expression as an independent predictive marker of sensitivity to tamoxifen. Mechanistically, we discovered that tamoxifen stimulates ERα methylation by PRMT5, a key event for its binding to corepressors such as SMRT and HDAC1, participating in the inhibition of the transcriptional activity of ERα. Although PRMT5 is mainly localized in the cytoplasm of tumor cells, our analyses show that tamoxifen triggers its nuclear translocation in tamoxifen‐sensitive tumors but not in resistant ones. Hence, we unveil a biomarker of sensitivity to tamoxifen in ERα‐positive breast tumors that could be used to enhance the response of breast cancer patients to endocrine therapy, by fostering its nuclear expression.
- 17 July 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (8) , e17248
Open AccessNuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of response to these anti‐estrogens to guide treatment decision. Here, using two independent cohorts of breast cancer patients, we identified nuclear PRMT5 expression as an independent predictive marker of sensitivity to tamoxifen. Mechanistically, we discovered that tamoxifen stimulates ERα methylation by PRMT5, a key event for its binding to corepressors such as SMRT and HDAC1, participating in the inhibition of the transcriptional activity of ERα. Although PRMT5 is mainly localized in the cytoplasm of tumor cells, our analyses show that tamoxifen triggers its nuclear translocation in tamoxifen‐sensitive tumors but not in resistant ones. Hence, we unveil a biomarker of sensitivity to tamoxifen in ERα‐positive breast tumors that could be used to enhance the response of breast cancer patients to endocrine therapy, by fostering its nuclear expression.
- Open Access
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
The social determinants associated with the advanced stage diagnosis of breast cancer in Egypt in the previous ten years: a single-center quantitative retrospective cohort study
Background: Breast cancer (BC) is the most common cancer among women worldwide. Most BC patients are diagnosed late in Egypt. This study aims to observe the socio-demographic inequalities associated with the advanced stage diagnosis of BC in Egypt in the previous ten years. Methods: This is a...
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
Open AccessThe social determinants associated with the advanced stage diagnosis of breast cancer in Egypt in the previous ten years: a single-center quantitative retrospective cohort study
Background: Breast cancer (BC) is the most common cancer among women worldwide. Most BC patients are diagnosed late in Egypt. This study aims to observe the socio-demographic inequalities associated with the advanced stage diagnosis of BC in Egypt in the previous ten years. Methods: This is a...
- Open Access
- 12 May 2022
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 16, 1388
Awareness and practices of Arab oncologists towards oncofertility in young women with cancer
Awareness and practices of Arab oncologists towards oncofertility in young women with cancer Loay Kassem1, Nawfel Mellas2, Marwan Tolba3, Matteo Lambertini
- 12 May 2022
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 16, 1388
Open AccessAwareness and practices of Arab oncologists towards oncofertility in young women with cancer
Awareness and practices of Arab oncologists towards oncofertility in young women with cancer Loay Kassem1, Nawfel Mellas2, Marwan Tolba3, Matteo Lambertini